112 related articles for article (PubMed ID: 15013720)
1. Genomic surgery for lung cancer.
Schrump DS
J Surg Res; 2004 Mar; 117(1):107-13. PubMed ID: 15013720
[TBL] [Abstract][Full Text] [Related]
2. Utilization of chromatin remodeling agents for lung cancer therapy.
Schrump DS; Hong JA; Nguyen DM
Cancer J; 2007; 13(1):56-64. PubMed ID: 17464247
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epigenome for the treatment of thoracic malignancies.
Schrump DS; Nguyen DM
Thorac Surg Clin; 2006 Nov; 16(4):367-77, vi. PubMed ID: 17240824
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic cancer therapy makes headway.
Mack GS
J Natl Cancer Inst; 2006 Oct; 98(20):1443-4. PubMed ID: 17047192
[No Abstract] [Full Text] [Related]
7. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
Herranz M; Esteller M
Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epigenome for the treatment and prevention of lung cancer.
Schrump DS; Nguyen DM
Semin Oncol; 2005 Oct; 32(5):488-502. PubMed ID: 16210090
[TBL] [Abstract][Full Text] [Related]
9. Chromatin modifying agents - the cutting edge of anticancer therapy.
Kwa FA; Balcerczyk A; Licciardi P; El-Osta A; Karagiannis TC
Drug Discov Today; 2011 Jul; 16(13-14):543-7. PubMed ID: 21664485
[TBL] [Abstract][Full Text] [Related]
10. Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.
Murakami J; Asaumi J; Maki Y; Tsujigiwa H; Kuroda M; Nagai N; Yanagi Y; Inoue T; Kawasaki S; Tanaka N; Matsubara N; Kishi K
Oral Oncol; 2004 Jul; 40(6):597-603. PubMed ID: 15063388
[TBL] [Abstract][Full Text] [Related]
11. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Gray SG; Al-Sarraf N; Baird AM; Cathcart MC; McGovern E; O'Byrne KJ
Eur J Cancer; 2009 Nov; 45(17):3087-97. PubMed ID: 19818596
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
14. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and gene silencing in cancer.
Baylin SB
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
[TBL] [Abstract][Full Text] [Related]
18. Reactivating the expression of methylation silenced genes in human cancer.
Karpf AR; Jones DA
Oncogene; 2002 Aug; 21(35):5496-503. PubMed ID: 12154410
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
